Abstract: At Ophthalmology Department of Civil Hospital of Culiacán, we investigated the inmediate effect of intravitreal injection of Bevacizumab on the IOP (intra ocular pressure) 30 min before and 24 h was measured after application of 0.1 mL of Bevacizumab (Avastin) to 67 patients under sterile technique in operating room, with topical anesthetic tetracaine at 3.5 mm from the sclerocorneal junction. Pre-application average IOP was 13.5 ± 2.6 mmHg, and post-implementation IOP was 13.8 ± 2.6 mmHg. Diagnostics: PDR + MESC (proliferative diabetic retinopathy with macular edema significant clinically) in 26 patients (38.8%), NPDRSC (nonproliferative diabetic retinopathy significant clinical) in 14 patients (20.9%), wet AMD (age related macular degeneration) in 14 patients (20.9%), OCRV (occlusion central retinal vein) in 3 patients (4.5%), OBRV (occlusion of branch retinal vein) in 3 patients (4.5%), SCChR (serous central chorioretinopathy) in 2 patients (4.5%), ChNnoA-R (choroidal neovascularization no age related) in 2 patients (3%), CME (cystoid macular edema) in 2 patients (3%).
Introduction


Angiogenesis is a process that is essential for various physiological processes, such as embryonic and postnatal growth, reproductive functions and the scarring of wounds [1] . Multiple studies in recent decades have established that this process requires a number of steps in endothelial cells and murals where numerous families of ligands involved. However, despite the complexity, VEGF (vascular endothelial growth factor) appears to be necessary for the growth of blood vessels in normal or pathological circumstances [2] .
Antiangiogenic Therapy
The abnormal growth of blood vessels, called
Corresponding author: Anthon Álvarez Arredondo, Ph.D., professor, research fields: pharmacology and toxicology. neovascularization, is a central feature of retinal disorders including retinopathy of prematurity, RVO (retinal venous occlusions), proliferative diabetic retinopathy and MDNEA-R (macular degeneration neovascular related to age), which are the leading causes of blindness in both childhood and productive adult life [3] . At present, it is known that inhibiting the angiogenic cascade and vascular permeability effective treatment in ocular neovascularization is achieved as in these pathologies [4] . It is noteworthy that, systemically, it is known that VEGF mRNA (messenger ribonucleic acid) is expressed in a wide variety of human tumors [5] . Then, it is known that this therapy is used successfully to treat different types of cancers such as colon cancer, gastrointestinal, kidney, among others [2] .
The introduction of VEGF inhibitors (anti-VEGF) in ophthalmology, represented progress in treating D DAVID PUBLISHING many retinal diseases, once deemed untreatable. Bevacizumab (Avastin) is a murine humanized monoclonal antibody that is directed against all biologically active isoforms of VEGF, there are many studies reporting complications of intravitreal antiangiogenic. One of the reported adverse effects is largely increased intra ocular pressure due to the intravitreal injection.
Applications in Ophthalmology
Retinopathy of Prematurity
This disease is the number one blind children in Latin America cause. The first major study comparing conventional laser treatment with intravitreal Bevacizumab was the BEAT-ROP, in which it was found that monotherapy with Bevacizumab (0.625 mg) compared with the laser, in infants with Stage 3+, showed benefits for the Area I, not for Zone II. It also noted that the peripheral retinal vessels continued to grow after treatment, contrary to laser treatment leading to a permanent destruction of the peripheral retina [6] . 
Proliferative Diabetes Retinopathy
There is currently a dose or treatment regimen specific so far [9] . They suggest that anti-VEGF can reduce the risk of intraocular hemorrhage in patients with PDR (proliferative diabetic retinopathy) [10] .
Materials and Methods
Under informed consent, measurements of intraocular pressure in patients undergoing intravitreal
Bevacizumab, 30 min before and 24 h after the application were made. 
Results and Analysis
It was made 98 applications in a total of 67 patients, average age of 65.4 years was obtained (Table 1) . Pre-application average IOP was 13.5 ± 2.6 mmHg, and post-implementation IOP was 13.8 ± 2.6 mmHg. There are 98 applications in a total of 67 patients, a total of 35 women, 52.2% representing sample and 32 men, 47.8% being the sample. An average age of 65.4 years was obtained with a standard deviation of 12.9 years, age range 31~89 years no statistical significance (p = 0.1810) was found (Fig. 1) . Visual acuity was 0.763 ± 0.600 logMAR scale, before application, compared to 0.700 ± 0.589 average (p = 0.008) (Fig. 2) . The most common vitreoretinal diseases were: PDR + MESC (proliferative diabetic retinopathy with macular edema significant clinically) at 38.8%, NPDRSC (nonproliferative diabetic retinopathy significant clinical) at 20.9%, macular degeneration related to age at 20.9% (Fig. 3) .
Complications found were subconjunctival hemorrhage in 39 events (39.8%), it increased IOP > 6 mmHg in one patient. 
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VA (visual acuity) logUnit Fig. 3 Vitreoretinal diseases distribution. DME: diabetic macular edema; AMD: age related macular degeneration; BVO: Branch retinal vein occlusion; CSCR: choroidal retinopathy central serous; CME: cystoid macular edema.
Discussion
In our study, we found no significant change in intraocular pressure before and after the application of 2.5 mg (0.1 mL) of intravitreal Bevacizumab. This is comparable to the results presented by Güler et al. [11] who analyzed the central thickness of the cornea, the simulated keratometry, the anterior chamber depth, the iridocorneal angle and intraocular pressure in patients who were applied a single dose of 2.5 mg (0.1 mL) of Bevacizumab.
Conclusions
The use of intravitreal Bevacizumab with a 2.5 mg/0.1 mL dose is a choice for patients with any retinal pathology with macular edema. Anti-VEGF therapy is the mainstay for the treatment of many retinal diseases. Despite its promising efficacy in halting the disease and improving the vision for the patients should consider the potential systemic and ocular risks and benefits of receiving intravitreal anti-VEGF therapy and closely monitoring the patients for adverse effects that may occur in the immediate or subsequent periods after administration of the drugs.
